Petros Pharmaceuticals Stock Current Asset
| PTPI Stock | USD 0.29 0.02 7.41% |
Petros Pharmaceuticals fundamentals help investors to digest information that contributes to Petros Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Petros Stock. The fundamental analysis module provides a way to measure Petros Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Petros Pharmaceuticals stock.
As of now, Petros Pharmaceuticals' Total Current Assets are increasing as compared to previous years. The Petros Pharmaceuticals' current Non Current Assets Total is estimated to increase to about 25.3 M, while Other Current Assets are projected to decrease to under 2.6 M. Petros | Current Asset |
Petros Pharmaceuticals Company Current Asset Analysis
Petros Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Petros Current Asset Historical Pattern
Today, most investors in Petros Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Petros Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Petros Pharmaceuticals current asset as a starting point in their analysis.
Petros Pharmaceuticals Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Petros Net Tangible Assets
Net Tangible Assets |
|
In accordance with the recently published financial statements, Petros Pharmaceuticals has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Petros Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Petros Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Petros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Petros Pharmaceuticals by comparing valuation metrics of similar companies.Petros Pharmaceuticals is currently under evaluation in current asset category among its peers.
Petros Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.60) % | ||||
| Current Valuation | 26.75 M | ||||
| Shares Outstanding | 10.01 M | ||||
| Shares Owned By Insiders | 8.10 % | ||||
| Shares Owned By Institutions | 2.20 % | ||||
| Number Of Shares Shorted | 199.19 K | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 5.82 M | ||||
| Gross Profit | 6.21 M | ||||
| EBITDA | (4.21 M) | ||||
| Net Income | (8.16 M) | ||||
| Cash And Equivalents | 13.3 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 8.28 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 3.10 X | ||||
| Book Value Per Share | 4.04 X | ||||
| Cash Flow From Operations | (7.63 M) | ||||
| Short Ratio | 0.72 X | ||||
| Earnings Per Share | (3.80) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | 2.28 | ||||
| Market Capitalization | 2.7 M | ||||
| Total Asset | 33.8 M | ||||
| Retained Earnings | (98.89 M) | ||||
| Working Capital | 9.62 M | ||||
| Net Asset | 33.8 M |
About Petros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:Check out Petros Pharmaceuticals Piotroski F Score and Petros Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.